Ontology highlight
ABSTRACT:
SUBMITTER: Raju GK
PROVIDER: S-EPMC7418461 | biostudies-literature | 2018 Jan
REPOSITORIES: biostudies-literature
Raju G K GK Gurumurthi Karthik K Domike Reuben R Kazandjian Dickran D Landgren Ola O Blumenthal Gideon M GM Farrell Ann A Pazdur Richard R Woodcock Janet J
Clinical pharmacology and therapeutics 20171120 1
Drug regulators around the world make decisions about drug approvability based on qualitative benefit-risk analysis. In this work, a quantitative benefit-risk analysis approach captures regulatory decision-making about new drugs to treat multiple myeloma (MM). MM assessments have been based on endpoints such as time to progression (TTP), progression-free survival (PFS), and objective response rate (ORR) which are different than benefit-risk analysis based on overall survival (OS). Twenty-three F ...[more]